An Open-label, Two Part Investigation of the Pharmacokinetics, Safety, and Tolerability of Alisporivir and EDP239 When Co-administered to Healthy Adult Subjects

Trial Profile

An Open-label, Two Part Investigation of the Pharmacokinetics, Safety, and Tolerability of Alisporivir and EDP239 When Co-administered to Healthy Adult Subjects

Completed
Phase of Trial: Phase I

Latest Information Update: 12 Jan 2015

At a glance

  • Drugs Alisporivir (Primary) ; EDP 239 (Primary)
  • Indications Hepatitis C
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors Novartis
  • Most Recent Events

    • 08 Jan 2015 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 19 Aug 2014 Planned End Date changed from 1 Oct 2014 to 1 Nov 2014 as reported by ClinicalTrials.gov.
    • 19 Aug 2014 Planned primary completion date changed from 1 Oct 2014 to 1 Nov 2014 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top